A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Public ClinicalTrials.gov record NCT04489771. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
Study identification
- NCT ID
- NCT04489771
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 154 participants
Conditions and interventions
Conditions
Interventions
- Belzutifan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 12, 2020
- Primary completion
- Feb 9, 2023
- Completion
- Oct 3, 2026
- Last update posted
- Feb 10, 2025
2020 – 2026
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Georgetown University Medical Center ( Site 0002) | Washington D.C. | District of Columbia | 20007 | — |
| Univ of Miami- Sylvester Comprehensive Cancer Center ( Site 0023) | Miami | Florida | 33136 | — |
| Norton Cancer Institute - St. Matthews ( Site 0025) | Louisville | Kentucky | 40207 | — |
| Weinberg Cancer Institute at Franklin Square ( Site 0007) | Baltimore | Maryland | 21237 | — |
| Cancer Partners of Nebraska ( Site 0003) | Lincoln | Nebraska | 68510 | — |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0012) | Omaha | Nebraska | 68130 | — |
| New York Oncology Hematology P.C ( Site 0028) | Albany | New York | 12206 | — |
| Roswell Park Cancer Institute ( Site 0038) | Buffalo | New York | 14263 | — |
| Fox Chase Cancer Center ( Site 0026) | Philadelphia | Pennsylvania | 19111 | — |
| Sanford Cancer Center Oncology Clinic ( Site 0031) | Sioux Falls | South Dakota | 57104 | — |
| UT West Cancer Center ( Site 0032) | Germantown | Tennessee | 38138 | — |
| Urology Associates ( Site 0015) | Nashville | Tennessee | 37209 | — |
| University of Texas Southwestern Medical Center at Dallas ( Site 0004) | Dallas | Texas | 75390 | — |
| Baylor Scott & White Medical Center - Temple ( Site 0013) | Temple | Texas | 76508 | — |
| Huntsman Cancer Institute ( Site 0037) | Salt Lake City | Utah | 84112 | — |
| Inova Schar Cancer Institute ( Site 0001) | Fairfax | Virginia | 22031 | — |
| Blue Ridge Cancer Care - Roanoke ( Site 0017) | Roanoke | Virginia | 24014 | — |
| Kadlec Clinic Hematology and Oncology ( Site 0008) | Kennewick | Washington | 99336 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04489771, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04489771 live on ClinicalTrials.gov.